Download the PDF version:

EN

|

DE

| IT

Luxembourg, Luxembourg - October 30, 2015 - Cosmo Pharmaceuticals S.A. (SIX: COPN) announced today that it has been informed by Mochida Pharmaceutical Co., Ltd., that Mochida has concluded the phase III clinical trials necessary for the submission of the registration in Japan and that Mochida had filed the NDA with the Japanese Ministry of Health, Labour and Welfare (MHLW). Mochida had licensed the product for Japan from Cosmo's sub-licensee Shire.

Upon registration, Cosmo would be eligible for low single digit royalties of up to a cumulative total of US$ 15 million.

About Cosmo Pharmaceuticals S.A.

Cosmo is a specialty pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected Gastrointestinal and topically treated Skin Disorders. The company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn's Disease, and Colon Infections. In addition, the Company is developing a diagnostic for the detection of colon cancer and a medical device for polyp excision as well as new chemical entities that are being developed by the associate company Cassiopea SpA for the topical treatment of skin diseases. Cosmo's MMX® products that have reached the market are Lialda®/Mezavant®/Mesavancol®, a treatment for IBD that is licensed globally to Giuliani and Shire Limited and Uceris®, the first glucocorticosteroid indicated for the induction of remission in active, mild to moderate Ulcerative Colitis, licensed in US to Salix and in the Rest of the World except for Japan to Ferring as Cortiment®. Cosmo's proprietary MMX® technology is at the core of the Company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in the colon. For further information on Cosmo, please visit the Company's website: www.cosmopharma.com

Financial agenda

Results 2015 7 March, 2016

AGM 23 March, 2016

Contact:

Dr. Chris Tanner, CFO and Head of Investor Relations

Cosmo Pharmaceuticals S.A.

Tel: +352 2784 87 49

ctanner@cosmopharma.com

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

Most computers will open PDF documents automatically, but you may need to download Adobe Reader.

distributed by